Showing 7741-7750 of 8355 results for "".
- UVBioTek Launches POLY Go Portable LED Light Therapyhttps://practicaldermatology.com/news/uvbiotek-launches-poly-go-portable-led-light-therapy/2457714/UVBioTek has launched a new line of hand-held LED therapy products that support their newest brand, POLY LED Light Therapy. The mobile hand-held products, named “POLY Go”, use multiple wavelengths that are clinically proven to cater to those with acne, fine-
- CBD Naturals to Introduce New Skincare Linehttps://practicaldermatology.com/news/cbd-naturals-to-introduce-new-skincare-line/2457717/Delivering natural beauty from the inside out, CBD Naturals® will introduce Floré™, a prestigious new line of skincare products, at the International Cannabis Business Conference in Vancouver on June 25. Floré™ incorporates cutting-edge ingredient formulas that
- New Data from DermTech Presented at International Investigational Dermatology Meetinghttps://practicaldermatology.com/news/new-data-from-dermtech-presented-at-international-investigational-dermatology-meeting/2457724/DermTech, Inc., has announced the publication of two clinical study abstracts at the 2018 International Investigational Dermatology meeting
- Opdivo Data: Superior Recurrence-Free Survival Versus Ipilimumabhttps://practicaldermatology.com/news/opdivo-data-superior-recurrence-free-survival-versus-ipilimumab/2457734/Updated results from the Phase 3 CheckMate -238 trial evaluating Opdivo (nivolumab, Bristol-Myers Squibb Company) versus Yervoy (ipilimumab, Bristol-Myers Squibb Company) in patients with stage IIIB/C or stage IV melanoma who are at high ri
- Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous Sclerosishttps://practicaldermatology.com/news/rapamycin-lotion-reduces-facial-tumors-caused-by-tuberous/2457750/Rapamycin lotion significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with tuberous sclerosis complex (TSC), researchers from The University of Texas Health Science Center at Houston (UTHealth) report. Findings of the multicenter, international stud
- Skincare on Trial: Revision Introduces New Patient-Friendly Optionhttps://practicaldermatology.com/news/skincare-on-trial-revision-introduces-new-patient-friendly-option/2457752/Revision Skincare has introduced a collection of five comprehensive 45-day trial regimens they say are designed to address the needs of
- FDA Greenlights Restylane Lyft for Hand Rejuvenationhttps://practicaldermatology.com/news/fda-greenlights-restylane-lyft-for-hand-rejuvenation/2457757/The US Food and Drug Administration has approved Restylane Lyft for use on the dorsal hands of people older than 21, making it the first hyaluronic acid (HA) injectable gel approved for this use. Radiesse (Calcium Hydroxylapatite) is also approved for the correction of lost
- Greater Skin Cancer Risk Seen in U.S. Military Personnelhttps://practicaldermatology.com/news/greater-skin-cancer-risk-seen-in-us-military-personnel/2457762/U.S. military personnel are more likely to develop skin cancer than the general population, according to a review of nine published studies in the Journal of the American Academy of Dermatology (JADD). The f
- Valeant is Becoming Bausch Health Companies, Inc.https://practicaldermatology.com/news/valeant-is-becoming-bausch-health-companies-inc/2457770/Bausch Health Companies, Inc. will become the new name of Valeant Pharmaceuticals International, Inc., effective in July 2018. Based on th
- Skin Cancer Foundation Hits the Roadhttps://practicaldermatology.com/news/skin-cancer-foundation-hits-the-road/2457771/The Skin Cancer Foundation kicks off the second year of its mobile education and screeing program called Destination: Healthy Skin. Starting Tuesday, May 15, in New York City, the tour will stop in 15 cities ov